Aurora Cannabis Inc., a leading cannabis company in Canada, through its subsidiary, Aurora Germany GmbH, and Ethypharm, a European pharmaceutical company, have successfully completed the delivery of their initial shipment of cannabis to the French medical cannabis pilot program. The idea of this transaction is to be able to serve and help a large number of patients in the coming weeks. The National Agency for the Safety of Medicines and Health Products (ANSM) selected the expertise of Aurora and Ethypharm to carry out this operation. Both were given the task of supplying the full range of dried medical cannabis flowers to patients living in France during the pilot program.
While it is true that cannabis has already become a more common topic in the world and its benefits have been echoed, Miguel Martin, CEO of Aurora Cannabis, assures that an operation like this is a significant step in providing access to patients, while also supporting the destigmatization of medical cannabis in France. “This achievement is another example of Aurora’s leadership in global cannabis, with a proven track record of supporting the advancement of international medical cannabis markets alongside government agencies. By demonstrating a deep commitment to compliance and a focus on product quality, we won three of the nine available bids. If successful, this pilot program could lead to one of the largest regulated medical cannabis markets in Europe,” Martin added.
Aurora Nordic, the production facility, is firmly committed to providing the necessary tools to develop sufficient and consistent supplies to healthcare professionals and patients for the pilot program. The agreement between Aurora and Ethypharm to serve the French pilot program was signed late last year and is an example of how the experience and expertise of both companies can be leveraged in an industry as important as the medical cannabis industry.